Small Time Potatoe

Retired and living the dream. I KILLED $CVM SHORTS and took it from $1 to $41!

[Small Time Potatoe @SmallTimePotato]

@Stocktwits @howardlindzon
The ceo of @Stocktwits said that is ok to call people the R word and spam the site

He isn’t concerned about house roles all is concerned about is his pocketbook look below

[Bizarro Geert @bizarro13620]

$IMMX just delivered one of the most stunning data drops at #ASH2025 🚀

NXC-201 posted a 75% CR rate in relapsed/refractory AL Amyloidosis — with potential to hit ~95% CR as pending patients read out.

Clean safety. Organ responses. RMAT + Orphan.

This isn’t incremental — this is first-and-best-in-class territory.🔥

https://t.co/Vp40E54Uyn

[Bizarro Geert @bizarro13620]

$IMMX just closed a $100M upsized offering at $5.10 — institutions drew a line in the sand. 🚀


This gives IMMX runway into 2027, right as ASH data hits.
Smart money wanted in before the catalyst.

Big cash. Big confidence. Big moment ahead. 🔬🔥

https://t.co/peQ0EXjRXM

[Monaco @monaco_biotech]

$IMMX
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results,Advancing Toward BLA Submission as a Potentially First- +Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
• BioPharmCatalyst

⁦@BiotechPort⁩ https://t.co/TCYZ048zz8

[FBCC @BiotechPort]

@Sanctuary_Bio The bispecifics are half of the efficacy (till now at least), nasty safety profile and chronic treatment.

I am not sure anyone is seriously developing bispecifics in this indication. $IMMX should be approved next year.

[FBCC @BiotechPort]

@Sanctuary_Bio $IMMX still looks better to me.

Bispecific needs 24 cycles monthly injections.

Also, it is not clear to me if AbbVie is pushing for approval in rr AL.
Will be interesting to compare the safety

[Bizarro Geert @bizarro13620]

$IMMX dropped its #ASH25 data first… and only after investors saw it did the company price a $100M UPSIZEDoffering at $5.10. 🔥

Upsized after data = real demand.

Funds reviewed the results and said: “We want MORE at this price.”

That’s conviction, not dilution. 🚀🧬

[Bizarro Geert @bizarro13620]

$IMMX delivers its biggest data day today

NEXICART-2 readout:

• 95% normalized markers in ≤14 days

• 14/16 MRD-negative by Day 25

• Cardiac/renal/hepatic responses

• Zero neurotox

• 19/20 in VGPR/CR

Plus new ASH BCMA-CAR T autoimmune data validating the same mechanism.

12/7/25 A date that will live in infamy for IMMX #ASH25 @Immixbiopharma

[Small Time Potatoe @SmallTimePotato]

@Anders_Research You were wrong then.

Just admit it

[🇺🇸Equity Analyst @JeesusCruz]

$IMMX isworthlong−termfocus.Marketcap
139.35M on Dec 3, P/B 16.86—higher than industry avg 4.54, but 5-yr capex growth 176%. Premium backed by R&D, focus on tracking.🚀🚀🚀
$MSTR $MU $AAPL
$SNDK $COIN $AMZN $AVGO
#STOCKS #StocksToWatch #AEWDynamite

[Bizarro Geert @bizarro13620]

🚨 $IMMX just dropped a new slide, not in Corp deck

NXC-201 now framed as a plasma cell–targeting platform for autoimmune: lupus, MG, RA, more.

#ASH25 still about AL, but the pivot is clear.

Low IL-6
Outpatient CAR-T
Huge potential

[Small Time Potatoe @SmallTimePotato]

@McnallieM @Immixbiopharma They also just released today their new Corporate Presentation

$immx

https://t.co/olGTFfoiVg

[Small Time Potatoe @SmallTimePotato]

$immx

Wow!

Monday it is, I guess.

Only two more training days and then we ride boys

[McNallie Money @McnallieM]

Great new podcast here featuring @Immixbiopharma!!! Definitely one to keep an eye on!!! 🧬🧬🧬 $IMMX

https://t.co/bNDgArPN7u

[McNallie Money @McnallieM]

Great new podcast here featuring @Immixbiopharma!!! Definitely one to keep an eye on!!! 🧬🧬🧬 $IMMX

https://t.co/bNDgArPN7u

[Small Time Potatoe @SmallTimePotato]

$cvm $djt

Little elf had no chance.

[Small Time Potatoe @SmallTimePotato]

@howardlindzon

[Coach Nick Money @CoachNickMoney]

$IMMX holding up above $4.50 with solid tape and 22M+ volume. Watching this one for strength above recent intraday resistance.

[Vanderbilt WBB @VandyWBB]

.@aubtheballer1 is quickly becoming a fan favorite 🫶

[Bizarro Geert @bizarro13620]

$immx

I encourage all to listen both conference webcasts from this week

“The cash (on hand) will take us thru end of trial, AND thru FDA feedback on the BLA we are submitting. We are in a great place financially���

BLA filed 1H26

Efficacy and durability updated at #ASH25

https://t.co/LZdpmCXuIE

[Bizarro Geert @bizarro13620]

$IMMX

AZ new AL amyloidosis CAR-T trial hasn’t even started recruiting.

IMMX already has U.S. patients treated, early efficacy, and an ASH oral.

AZ is concept stage.

IMMX is clinical stage. The gap isn’t months — it’s years. First-mover advantage is real.

#ASH25

https://t.co/pdGHiWNogM